752 Views | 151 Downloads
Correspondence: Donald L. Bliwise, Ph.D., Department of Neurology, Emory University School of Medicine, 1841 Clifton Road, Room 509, Atlanta, Georgia 30329; Phone: 404-728-4751; Fax: 404-712-8145; Email: dbliwis@emory.edu.
Acknowledgments: Some patients were recruited from the Parkinson Progression Markers Initiative.
Disclosures: Bliwise is a consultant for Ferring.
Trotti is a consultant for UCB.
Factor is a consultant for Boehringer Ingelheim, Merz, and Ipsen; receives royalties from Demos and Blackwell Futura; and is a paid editor for Current Treatment Options in Neurology and Current Neurology and Neuroscience.
Freeman serves on the advisory board for Metz, Ipsen, Allergan, and UCB.
Rye is a consultant for UCB and Merck.
This work was supported by R01 NS-050595 (DLB); UL1 RR-025008/KL2 RR-025009 (Atlanta Clinical and Translational Science Institute); and U01 NS-050324 (CoQ10 trial).
Juncos has received grants from Chelsea and Allon.
Factor has received grants from TEVA, EMD Serono, Ipsen, Ceregene, Allergan, and Medtronics.
Freeman has received grants from EMD Serono and Phytopharm.
© 2012 Elsevier Ltd. All rights reserved.